Literature DB >> 30134015

Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides.

Christian Steinebach1, Agnieszka Ambrożak1, Stefan Dosa1, Shaunna L Beedie2, Jonathan D Strope2, Gregor Schnakenburg3, William D Figg2, Michael Gütschow1.   

Abstract

The introduction of fluorine into bioactive molecules is a matter of importance in medicinal chemistry. In this study, representatives of various chemical entities of fluoroaromatic n class="Chemical">compounds were synthesized. Depending on the reaction conditions, either tetrafluorophthalimides or ammonium tetrafluorophthalamates are accessible from tetrafluorophthalic anhydride and primary amines. Tetrafluorophthalamic acids undergo thermal decarboxylation to yield tetrafluorobenzamides. These could be successfully converted upon treatment with primary amines, in the course of an aromatic nucleophilic substitution, to 2,3,5-trifluorobenzamides with respective amino substituents at the 4-position. The five structure types were characterized by means of spectroscopic and crystallographic methods. The synthesized compounds were evaluated as inhibitors of angiogenesis by measuring microvessel outgrowth in a rat aortic ring assay. The biological activity was maintained throughout these different polyfluorinated chemotypes.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  angiogenesis; fluorine; tetrafluorobenzamides; tetrafluorophthalimides; trifluorobenzamides

Mesh:

Substances:

Year:  2018        PMID: 30134015      PMCID: PMC6631341          DOI: 10.1002/cmdc.201800263

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  30 in total

1.  Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.

Authors:  M Gütschow; T Hecker; A Thiele; S Hauschildt; K Eger
Journal:  Bioorg Med Chem       Date:  2001-04       Impact factor: 3.641

2.  The many roles for fluorine in medicinal chemistry.

Authors:  William K Hagmann
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

Review 3.  Targeting angiogenesis with compounds from the extracellular matrix.

Authors:  Dorina Belotti; Chiara Foglieni; Andrea Resovi; Raffaella Giavazzi; Giulia Taraboletti
Journal:  Int J Biochem Cell Biol       Date:  2011-08-17       Impact factor: 5.085

4.  Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.

Authors:  Florencia Zalazar; Paola De Luca; Kevin Gardner; William D Figg; Roberto Meiss; Raul G Spallanzani; Pablo Vallecorsa; Belen Elguero; Javier Cotignola; Elba Vazquez; Adriana De Siervi
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

5.  Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.

Authors:  S Kumar; N Raje; T Hideshima; K Ishitsuka; A Roccaro; N Shiraishi; M Hamasaki; H Yasui; N C Munshi; P Richardson; W D Figg; K C Anderson
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

6.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis.

Authors:  Anil K Podichetty; Stefan Wagner; Sandra Schröer; Andreas Faust; Michael Schäfers; Otmar Schober; Klaus Kopka; Günter Haufe
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

8.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Authors:  Christina Therapontos; Lynda Erskine; Erin R Gardner; William D Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

9.  Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.

Authors:  Sylvia S W Ng; Gordon R MacPherson; Michael Gütschow; Kurt Eger; William D Figg
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

10.  Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.

Authors:  Shaunna L Beedie; Chris Mahony; Heather M Walker; Cindy H Chau; William D Figg; Neil Vargesson
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

View more
  3 in total

1.  On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.

Authors:  Christopher Heim; Samuel Maiwald; Christian Steinebach; Matthew K Collins; Jonathan Strope; Cindy H Chau; William D Figg; Michael Gütschow; Marcus D Hartmann
Journal:  Biochem Biophys Res Commun       Date:  2020-12-10       Impact factor: 3.575

2.  High-affinity Cu(I) chelator PSP-2 as potential anti-angiogenic agent.

Authors:  Dorothea M Heuberger; Shefali Harankhedkar; Thomas Morgan; Petra Wolint; Maurizio Calcagni; Barry Lai; Christoph J Fahrni; Johanna Buschmann
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

3.  Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs.

Authors:  Megan L Peach; Shaunna L Beedie; Cindy H Chau; Matthew K Collins; Suzana Markolovic; Weiming Luo; David Tweedie; Christian Steinebach; Nigel H Greig; Michael Gütschow; Neil Vargesson; Marc C Nicklaus; William D Figg
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.